Glucagon-like peptide-1 receptor agonist-induced lipidome remodelling is associated with improved liver, kidney and inflammatory markers in type 2 diabetes
Authors:
- Daria LipskaDLDaria Lipska
- Tommi SuvitaivalTSTommi Suvitaival
- Simon Maria KienleSKSimon Maria Kienle
- Bernt Johan von ScholtenBSBernt Johan von Scholten
- Rasmus Sejersten RipaRRRasmus Sejersten Ripa
- Emilie Hein ZobelEZEmilie Hein Zobel
- Joachim StørlingJoachim Størling
- Martin Bæk BlondMBMartin Bæk Blond
- Tarunveer S. AhluwaliaTATarunveer S. Ahluwalia
- Tine Willum HansenTHTine Willum Hansen
- Lotte Bjerre KnudsenLKLotte Bjerre Knudsen
- Mads Almose RøpkeMRMads Almose Røpke
Preprint
Abstract
Introduction: Lipids are considered both drivers and biomarkers of cardiometabolic diseases. As glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for diabetes and obesity management, it is crucial to understand how they affect the related comorbidities through the circulating lipidome. This study investigated the lipidomic changes induced by liraglutide treatment when compared to placebo in people with type 2 diabetes (T2D) to characterise lipid remodelling and its association with clinical outcomes. Research design and methods: This post-hoc study analysed plasma samples using liquid chromatography-mass spectrometry (LC-MS/MS) from LIRAFLAME, a randomised, double-blind, placebo-controlled, parallel-group trial. A hundred people with T2D received up to 1.8 mg of liraglutide or placebo once daily for 26 weeks. Plasma samples were collected at baseline, week 13 and week 26. Results: Liraglutide treatment resulted in a statistically significant increase in multiple lysophospholipid subclasses, including LPCs, LPC(O)s, LPC(P)s, LPEs, and LPE(P)s, observed at 13 weeks and sustained at 26 weeks compared to placebo. These increases were not mediated by the change in BMI. Triglyceride concentrations decreased at 13 weeks, while fatty acid levels declined at 26 weeks, consistent with enhanced lipid remodelling. The increase in LPC(O)s was associated with favourable decreases in ALAT, MCP-1, and UACR, suggesting anti-inflammatory effects with hepatic, renal, and cardiovascular benefits. Conclusions: Compared to placebo, 26 weeks of liraglutide treatment resulted in a favourable lipidomic shift from a triglyceride-rich profile towards one enriched in lysophospholipids. This lipid remodelling was associated with improvements in hepatic, renal, and inflammatory markers. Graphical Highlights: Liraglutide upregulates lysophospholipids and lowers triglycerides and fatty acids. The strongest increase was in lysoalkylphosphatidylcholines (LPC(O)s). Lysophosphatidylcholines (LPCs) increased independently of weight loss. LPC(O/P)s associated with improvements in liver, kidney, and inflammation markers.Keywords
Funding Information
- Skibsreder Per Henriksen, R. Oghustrus fund
This publication has 58 references indexed in Scilit:
- The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directionseClinicalMedicine, 2025
- The Role of GLP-1RA Medications in Medical Weight Loss and the Positive Impacts on Lipid ManagementCurrent Cardiovascular Risk Reports, 2025
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Lysophospholipids and their producing enzymes: Their pathological roles and potential as pathological biomarkersPharmacology & Therapeutics, 2023
- GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal veinMolecular Metabolism, 2022
- Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different mannerMolecular and Cellular Endocrinology, 2018
- Lipidome as a predictive tool in progression to type 2 diabetes in Finnish menMetabolism, 2018
- 2- OMe -lysophosphatidylcholine analogues are GPR119 ligands and activate insulin secretion from βTC-3 pancreatic cells: Evaluation of structure-dependent biological activityBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2018
- Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humansObesity, 2016
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trialDiabetologia, 2009